Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :15567494
Publication Date : //

Assembly and budding of influenza virus.


Influenza viruses are causative agents of an acute febrile respiratory disease called influenza (commonly known as "flu") and belong to the Orthomyxoviridae family. These viruses possess segmented, negative stranded RNA genomes (vRNA) and are enveloped, usually spherical and bud from the plasma membrane (more specifically, the apical plasma membrane of polarized epithelial cells). Complete virus particles, therefore, are not found inside infected cells. Virus particles consist of three major subviral components, namely the viral envelope, matrix protein (M1), and core (viral ribonucleocapsid [vRNP]). The viral envelope surrounding the vRNP consists of a lipid bilayer containing spikes composed of viral glycoproteins (HA, NA, and M2) on the outer side and M1 on the inner side. Viral lipids, derived from the host plasma membrane, are selectively enriched in cholesterol and glycosphingolipids. M1 forms the bridge between the viral envelope and the core. The viral core consists of helical vRNP containing vRNA (minus strand) and NP along with minor amounts of NEP and polymerase complex (PA, PB1, and PB2). For viral morphogenesis to occur, all three viral components, namely the viral envelope (containing lipids and transmembrane proteins), M1, and the vRNP must be brought to the assembly site, i.e. the apical plasma membrane in polarized epithelial cells. Finally, buds must be formed at the assembly site and virus particles released with the closure of buds. Transmembrane viral proteins are transported to the assembly site on the plasma membrane via the exocytic pathway. Both HA and NA possess apical sorting signals and use lipid rafts for cell surface transport and apical sorting. These lipid rafts are enriched in cholesterol, glycosphingolipids and are relatively resistant to neutral detergent extraction at low temperature. M1 is synthesized on free cytosolic polyribosomes. vRNPs are made inside the host nucleus and are exported into the cytoplasm through the nuclear pore with the help of M1 and NEP. How M1 and vRNPs are directed to the assembly site on the plasma membrane remains unclear. The likely possibilities are that they use a piggy-back mechanism on viral glycoproteins or cytoskeletal elements. Alternatively, they may possess apical determinants or diffuse to the assembly site, or a combination of these pathways. Interactions of M1 with M1, M1 with vRNP, and M1 with HA and NA facilitate concentration of viral components and exclusion of host proteins from the budding site. M1 interacts with the cytoplasmic tail (CT) and transmembrane domain (TMD) of glycoproteins, and thereby functions as a bridge between the viral envelope and vRNP. Lipid rafts function as microdomains for concentrating viral glycoproteins and may serve as a platform for virus budding. Virus bud formation requires membrane bending at the budding site. A combination of factors including concentration of and interaction among viral components, increased viscosity and asymmetry of the lipid bilayer of the lipid raft as well as pulling and pushing forces of viral and host components are likely to cause outward curvature of the plasma membrane at the assembly site leading to bud formation. Eventually, virus release requires completion of the bud due to fusion of the apposing membranes, leading to the closure of the bud, separation of the virus particle from the host plasma membrane and release of the virus particle into the extracellular environment. Among the viral components, M1 contains an L domain motif and plays a critical role in budding. Bud completion requires not only viral components but also host components. However, how host components facilitate bud completion remains unclear. In addition to bud completion, influenza virus requires NA to release virus particles from sialic acid residues on the cell surface and spread from cell to cell. Elucidation of both viral and host factors involved in viral morphogenesis and budding may lead to the development of drugs interfering with the steps of viral morphogenesis and in disease progression.

Authors : Nayak Debi P , Hui Eric Ka-Wai , Barman Subrata ,

Related products :

Catalog number Product name Quantity
orb81796 Influenza Virus H1N1 New Caledonia 20_99 IV 116 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_ New Caledonia_20_99 IVR 116. The Influenza Virus was 10
orb81791 Influenza Virus Victoria 504_00 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain B_Victoria_504_00. The Influenza Virus was purified by Ultracentrifugat 10
orb81794 Influenza Virus Florida 04_06 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain B_Florida_04_06. The Influenza Virus was purified by Ultracentrifugation 10
orb81789 Influenza Virus Qingdao 102_91 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain B_Qingdao_102_91. The Influenza Virus was purified by Ultracentrifugatio 10
orb81793 Influenza Virus Florida 07_04 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain B_Florida_07_04. The Influenza Virus was purified by Ultracentrifugation 10
orb81792 Influenza Virus Malaysia 2506_04 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain B_Malaysia_2506_04. The Influenza Virus was purified by Ultracentrifug 10
orb81790 Influenza Virus Tokio 53_99 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain B_Tokio_53_99. The Influenza Virus was purified by Ultracentrifugation with 10
orb81802 Influenza Virus H3N2 Wisconsin 67_05 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Wisconsin_67_05. The Influenza Virus was purified by Ultracentri 10
orb81799 Influenza Virus H3N2 Shangdong 9_93 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Shandong_9_93. The Influenza Virus was purified by Ultracentrifug 10
orb81801 Influenza Virus H3N2 Panama 2007_99 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Panama_2007_99. The Influenza Virus was purified by Ultracentrifu 10
orb81797 Influenza Virus H1N1 Taiwan 1_86 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Taiwan_1_86. The Influenza Virus was purified by Ultracentrifugation 10
orb81795 Influenza Virus H1N1 Beijing 262_95 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Beijing_262_95. The Influenza Virus was purified by Ultracentrifu 10
orb81803 Influenza Virus H3N2 Brisbane 10_07 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Brisbane_10_07. The Influenza Virus was purified by Ultracentrifu 10
iha-013 Recombinant Hemagglutinin-Influenza A Virus H9N2 Hong Kong 1073_99 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-013 Recombinant Hemagglutinin-Influenza A Virus H9N2 Hong Kong 1073_99 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-013 Recombinant Hemagglutinin-Influenza A Virus H9N2 Hong Kong 1073_99 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-031 Recombinant Hemagglutinin-Influenza A Virus H1N1 Solomon Island 03_2006 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-031 Recombinant Hemagglutinin-Influenza A Virus H1N1 Solomon Island 03_2006 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-031 Recombinant Hemagglutinin-Influenza A Virus H1N1 Solomon Island 03_2006 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-014 Recombinant Hemagglutinin-Influenza A Virus H1N1 California 04_2009 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-019 Recombinant Hemagglutinin-Influenza A Virus H1N1 New York 3571_2009 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-012 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wyoming 3_03 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-014 Recombinant Hemagglutinin-Influenza A Virus H1N1 California 04_2009 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-001 Recombinant Hemagglutinin-Influenza A Virus H1N1 New Caledonia 20_99 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-010 Recombinant Hemagglutinin-Influenza A Virus H5N1 Vietnam 1203_04 VIRAL ANTIGENS- INFLUENZA VIRUS 10


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur